Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis

Gema Fernández‐Juárez(Hospital Universitario Fundación Alcorcón), Javier Villacorta Pérez(Hospital Universitario Fundación Alcorcón), Fernando Caravaca‐Fontán(Hospital Universitario 12 De Octubre), Luís F. Quintana(Hospital Clínic de Barcelona), Amir Shabaka(Hospital Clínico San Carlos), Eva Rodríguez(Hospital Del Mar), Liliana Gadola(Universidad de la República de Uruguay), Alberto de Lorenzo(Hospital Universitario de Getafe), María Ángeles Cobo(Hospital Universitario de Canarias), Aniana Oliet(Hospital Universitario Severo Ochoa), Milagros Sierra(Hospital San Pedro), Carmen Cobelo(Hospital Universitario Lucus Augusti), Elena Iglesias(Complejo Hospitalario de Ourense), Miguel Blasco(Hospital Clínic de Barcelona), C. Galéano(Hospital Universitario Ramón y Cajal), Alfredo Cordon(Hospital Universitario Fundación Alcorcón), Jesús Oliva(Instituto de Salud Carlos III), Manuel Praga(Hospital Universitario 12 De Octubre), on behalf of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)
Clinical Journal of the American Society of Nephrology
November 5, 2018
Cited by 129Open Access
Full Text

Abstract

Background and objectives Drug-induced acute interstitial nephritis represents an emerging cause of acute kidney disease, especially among polymedicated elderly patients. Although corticosteroids are frequently used, controversy exists about the timing of initiation, efficacy, safety, and duration of treatment. Design, setting, participants, & measurements We performed a retrospective study of 182 patients with biopsy-proven drug-induced acute interstitial nephritis from 13 Spanish centers. Exposure was defined as the length of corticosteroid treatment. The main outcome was the level of serum creatinine at month 6, with respect to baseline values. Results The most common offending agents were nonsteroidal anti-inflammatory drugs (27%). In 30% of patients, the offending drug could not be identified. The median time to suspected drug withdrawal was 11 days (interquartile range, 5–22). All patients presented with acute kidney disease and were treated with corticosteroids. The mean initial dose of prednisone was 0.8±0.2 mg/kg per day. High-dose corticosteroid treatment was maintained for 2 weeks (interquartile range, 1–4). After 6 months, the mean recovered GFR was 34±26 ml/min per 1.73 m 2 and ten patients required maintenance dialysis. Use of high-dose corticosteroids for 3 weeks or treatment duration >8 weeks were not associated with better recovery of kidney function. In the multivariable analysis, delayed onset of steroid treatment (odds ratio, 1.02; 95% confidence interval, 1.0 to 1.04) and the presence of interstitial fibrosis of >50% on the kidney biopsy specimen (odds ratio, 8.7; 95% confidence interval, 2.7 to 27.4) were both associated with serum creatinine level at month 6 of >75%, with respect to baseline values. Conclusions High-dose corticosteroid treatment for 3 weeks or prolonged treatment for >8 weeks were not associated with greater kidney function recovery in drug-induced acute interstitial nephritis. A delay in the initiation of corticosteroids resulted in worse recovery of kidney function.


Related Papers

No related papers found

Powered by citation graph analysis